Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis

In conclusion, CIKs infusion is an effective adjuvant immunotherapy for enhancing the prognosis of NPC patients who have received the standard treatment, particularly for those with more aggressive tumor (T3/4) or advanced TNM stage.

Source: Journal of Cancer - December 14, 2018 Category: Cancer & Oncology Authors: Jing-Jing Zhao, Shu Zhou, Chang-Long Chen, Hong-Xia Zhang, Zi-Qi Zhou, Zheng-Rong Wu, Yuan Liu, Qiu-Zhong Pan, Qian Zhu, Yan Tang, Jian-Chuan Xia, De-Sheng Weng Tags: Research Paper Source Type: research